As the complexity of biotherapeutics continues to increase, so too does the level of characterization needed. Now more than ever, robust RP, SEC, HILIC and IEX solutions and workflows are essential.
This webinar will introduce a novel bio-inert hardware and a new LC column portfolio that is based on three highly efficient, yet complementary particle platforms and a flexible collection of orthogonal surface chemistries. This new HPLC/UHPLC column portfolio for biologics, aptly named bioZen, focuses on providing improved reproducibility, resolution, and performance across major protein characterization techniques.
The expert panelist will discuss biologic and biosimilar applications including size exclusion of aggregates, intact mass and middle down of mAbs, peptide mapping for SVA, glycan mapping by N-linked Glycan release, and charge variant analysis. She will also introduce a bio-inert column hardware that mitigates non-specific protein adsorption and minimizes the need for priming; leading to improved robustness and higher quality of methods and data.
You will learn about:
- The impact of hardware on sample recovery and priming
- New HPLC/UHPLC column portfolio for analysis of mAbs, ADCs and impurities
- Novel bio-inert hardware that minimizes non-specific protein adsorption and the need for time consuming priming protocols
- Good practices for improving major characterization workflows including peptide mapping, size exclusion, intact mass, intact fragment analysis, DAR, charge heterogeneity, and n-glycan analysis
Who should attend:
- All scientists or analysts that are currently characterizing proteins using HPLC or UHPLC